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The effects of amiodarone in a low dosage (200 mg every 8 h 
for 2 weeks, then 200 mglday) was assessed in a double- 
blind placebo-controlled trial in 34 patients with a history 
of severe congestive heart failure but no sustained ventric- 
ular arrhythmia. Left ventricular ejection fraction, tread- 
mill exercise tolerance and 48 h electrocardiographic mon- 
itoring were assessed before and repeatedly after beginning 
amiodarone or placebo therapy over 6 months, and side 
effects were monitored. 
In patients receiving amiodarone, the ejection fraction 
increased significantly from 19 f 7 to 29 f 15% at 6 
months (p < 0.01 from baseline), but not significantly in 14 
placebo-treated patients (18 -C 5 to 22 2 9%). Exercise 
tolerance increased significantly in amiodarone-treated pa- 
tients (median 433 s to 907 s, p < O.OS), but not significantly 
in placebo-treated patients (757 to 918 s). Nonsustained 
Severe congestive heart failure is associated with a high 
mortality rate. With traditional therapy, mainly digitalis and 
diuretic drugs, cardiac mortality has been reported (1) as 
being 30 to 50% after 1 year and 60 to 70% at 2 years. At least 
a third of the deaths are due to sudden ventricular arrhyth- 
mia. The use of vasodilators, in particular angiotensin- 
converting enzyme inhibitors, has been shown (2) to reduce 
the overall cardiac mortality rate, but not the incidence of 
sudden arrhythmic death. 
Patients with severe heart failure have a high frequency of 
ventricular ectopic activity and display runs of nonsustained 
ventricular tachycardia on electrocardiographic (ECG) mon- 
itoring, often without symptoms (3). The frequency and 
severity of arrhythmias are generally related to the severity 
of the heart failure (1) making determination as to whether 
they are independent risk factors for mortality difficult to 
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ventricular tachycardia was present in 88% of amiodarone- 
treated patients before, but in only 21% of patients after 6 
months of treatment (p = 0.06); it was seen in 43% of 
placebo-treated patients at baseline and in 50% after 6 
months. Fifty percent of amiodarone-treated patients had 
side effects (principally nausea) and the drug was with- 
drawn in 28% of cases; no life-threatening effects were 
seen. 
Low dose amiodarone appears to have a multifaceted 
potential to produce benefits in arrhythmia control, exer- 
cise tolerance and ventricular function in patients with a 
history of severe congestive heart failure, but better control 
of side effects (principally nausea) appears essential. Effects 
on mortality could not be determined from this study; such 
assessment requires a larger cohort of patients. 
(J Am Co11 Cardiol1989;14:1768-74) 
assess. However, frequent runs of ventricular tachycardia 
have been related to sudden death (4). Suppression of 
ventricular arrhythmias may reduce the incidence of sudden 
death, but to date, the role of antiarrhythmic therapy in 
patients with heart failure has been controversial (5). A 
widespread opinion is that conventional antiarrhythmic 
agents (for example, class I agents) are too often associated 
with further myocardial depression, proarrhythmic potential 
and unacceptable side effects to be recommended for routine 
prophylactic use in patients with heart failure with frequent 
asymptomatic ventricular arrhythmias, and they may also be 
ineffective (3). 
Amiodarone, principally a class III antiarrhythmic agent, 
has been used extensively in patients with life-threatening 
sustained ventricular arrhythmias (6). It has proven efficacy 
in patients resistant to other antiarrhythmic drugs, without 
producing a high incidence of proarrhythmia (7) or impairing 
ventricular function (8). It has vasodilator properties that 
may benefit a patient with severe heart failure. On the other 
hand, it is a drug with widespread side effects. 
The role of amiodarone is reducing ventricular arrhyth- 
mias in patients with severe heart failure and its effective- 
ness as a prophylactic agent against sudden arrhythmic 
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death have only just begun to be explored (9-12). However, 
before large-scale studies of mortality are pursued, further 
information relating to the effects of amiodarone in patients 
with heart failure is required, as relevant data from system- 
atic studies are, in fact, quite limited. There must be some 
compromise between a dose of amiodarone low enough to 
minimize side effects and minimal doses required to prevent 
a fatal arrhythmia in these patients. Also, given the deranged 
clinical status and biochemistry of patients with severe heart 
failure, the detection of side effects from amiodarone is 
likely to be ditficult. 
In this study, we chose a relatively low dose of amio- 
darone (200 mg every 8 h for 2 weeks, then 200 mgday) 
likely to be the best compromise between safety and ethcacy 
in patients with heart failure. We investigated its effects in a 
double-blind placebo-controlled trial in patients with a his- 
tory of severe heart failure stabilized on optimal medical 
therapy usually including digoxin, diuretic drugs and an 
angiotensin-converting enzyme inhibitor. The effects of ami- 
odarone or placebo were repeatedly assessed by measure- 
ments of left ventricular ejection fraction, exercise tolerance 
and ambulatory ECG monitoring, and side effects were 
evaluated. From the data, we hoped to determine any 
potential for the prophylactic use of a low dose of amio- 
darone to benefit patients with heart failure. 
Methods 
Study patients. Thirty-four patients aged 55 to 76 years 
were randomized into the trial between 1985 and 1987 with 
their informed consent. They were recruited from the clini- 
cal practice of the principal author, and all suitable patients 
were asked to participate. Excluded from consideration 
were patients who refused to provide consent or were unable 
to participate in a program of repeated assessment over a 6 
month period, including New York Heart Association func- 
tional class IV patients showing rapid deterioration. All 
recruited patients had a history of heart failure of a duration 
varying from 2 months to 4 years. Each had reached func- 
tional class IV status before entry into the trial; however, the 
majority had improved to a better functional class before 
randomization, principally as a result of vasodilator therapy, 
but all still had a left ventricular ejection fraction ~27%. 
Medical therapy was optimized and was stable before trial 
entry. No patient had a history of a symptomatic sustained 
ventricular arrhythmia. 
Baseline characteristics (Table 1). Originally, 19 patients 
were randomized to amiodarone and 15 patients to placebo. 
The imbalance arose by chance from a 50 patient random- 
ization scheme. There were four early withdrawals within 
the first few days of therapy, leaving 16 patients on amio- 
darone and 14 on placebo for repeated assessment and 
long-term follow-up. In these two patient groups, small and 
insignificant differences (p > 0.05) were seen in mean age. 
Table 1. Clinical Characteristics of 30 Patients 
Amiodarone Placebo 
(n = 16) (n = 14) 
Age (yr) 55 to 76 (mean 70) 50 to 75 (mean 66) 
Cardiac diagnosis IDC x 4 
IHD 8 IO 
Functional class before entry II 4 3 
111 II IO 
IV I I 
LVEF at baseline (%) IO to 26 (mean 19) Y to 26 (mean 17) 
Concurrent drug therapy (no.) 
Digoxin 10 s 
ACE inhibitor 13 IO 
Prazosin 2 2 
Nitrate 4 8 
Warfarin 2 2 
ACE = angiotensin-converting enzyme: IDC = idiopathic dilated cardio- 
myopathy: IHD = ischemic heart disease; LVEF = left ventricular ejection 
fraction. 
proportion of patients with ischemic heart disease and con- 
current drug therapy. Importantly, ejection fraction (~27%) 
and functional classification were directly comparable be- 
tween the amiodarone and placebo groups. 
Investigations. Nuclear cardiac gated blood pool scans. 
These were performed in three views using technetium-99m. 
The left ventricular ejection fraction was calculated from the 
left anterior oblique view, using a semiautomated modifica- 
tion of a standard technique (13). In our laboratory, the 
reproducibility of the ejection fraction obtained on two 
separate occasions in a patient in a stable cardiac state has 
been within 3% for an ejection fraction <40%, comparable 
with previously published data (13). End-diastolic and end- 
systolic pixel size was used as an estimate of ventricular 
size, and serially compared for a given patient but not 
between patients because of technical factors. 
48 h umbulatory ECG monitoring. This was performed 
using a Marquette 8000T system, including full disclosure of 
all recorded information. 
Exercisr treadmill testing. Using a Naughton protocol, 
the test was performed up to a maximum of 1,260 s (21 min). 
Thyroid function tests. Serum thyroid stimulating hor- 
mone. free thyroxine and free tri-iodothyronine were mea- 
sured. 
Statistical analysis. Differences in ejection fraction, car- 
bon monoxide diffusing capacity and selected patient char- 
acteristics were analyzed using unpaired t tests and analysis 
of variance. Aligned ranks nonparametric test and Wilcoxon 
analysis were employed on exercise tolerance data in vari- 
ous contexts. Ventricular arrhythmias and selected patient 
characteristics were subjected to chi-square analysis. 
Hespirutory function tests. Forced expiratory volume in 
1 s. vital capacity and carbon monoxide diffusing capacity 
corrected for hemoglobin and lung volume were measured. 
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Figure 1. Changes in left ventricular ejection fraction (LVEF) are 
shown for 16 amiodarone-treated patients (left panel) and 14 place- 
bo-treated patients (right panel). Individual data points and their 
mean ? standard deviation are shown before drug therapy (PRE) 
and after 6 weeks and 6 months of therapy, with p values for any 
change from pre-treatment values. Significant increases were seen in 
amiodarone-treated patients, but not in placebo-treated patients. 
Ventricular Function and Exercise Tolerance 
Selected liver function tests. These measured serum 
bilirubin, aspartate transaminase, gamma glutaryl transfer- 
ase and alkaline phosphatase. 
Blood nitrogens. Urea, creatinine and electrolytes were 
measured. 
Protocol. The ejection fraction, ECG monitoring and 
exercise tests were repeated after 6 weeks and 6 months of 
treatment. Tests of thyroid, respiratory and hepatic function 
were repeated after 6 weeks, 3 months and 6 months. Blood 
urea, creatinine and electrolyte measurements were re- 
peated frequently, as clinically indicated. Scheduled patient 
visits occurred at 2 weeks, 6 weeks and every 3 months 
thereafter during long-term follow-up study. Changes in 
concurrent medication were minimized and limited to minor 
adjustments of diuretic dosage. The double-blind nature of 
the trial was maintained as far as possible. Warfarin dosage 
was independently adjusted at the beginning of treatment by 
the hematology department, and the dose of warfarin was 
not discussed between patient and investigator. The dose of 
digoxin was routinely halved in all patients receiving it. The 
trial protocol was approved by the Human Ethics Committee 
of the hospital in August 1985. 
Ejection fraction and ventricular size. The progressive 
changes in ejection fraction over the 6 month observation 
period are shown in Figure 1. The amiodarone-treated 
patients had a mean ejection fraction at baseline of 19 ? 7%; 
this increased to 25 + 9% at 6 weeks and 29 + 15% at 6 
months. These increases from baseline values were both 
statistically significant (p < 0.01). The placebo-treated pa- 
tients had a mean ejection fraction of 18 +- 5% at baseline, 
increasing to 21 ? 8% at 6 weeks and 22 +- 9% at 6 months. 
However, this increase was not statistically significant. An 
increase in ejection fraction by 20% or more could be 
considered clinically significant, and exceeds the variability 
of repeated measurements of ejection fraction in a given 
patient. As such, the percent of patients showing such an 
increase was 56% in the amiodarone group versus 39% in the 
placebo group at 6 weeks and 71 versus 25%, respectively, at 
6 months. 
Results 
Clinical data (monitoring of ventricular arrhythmias, ejec- 
tion fraction and exercise tolerance) were complete for all 
patients except: I) an amiodarone-treated patient withdrawn 
after 6 weeks, with no 6 month data; 2) two placebo-treated 
patients who died between 6 weeks and 6 months; 3) three 
placebo-treated patients unable to exercise because of ar- 
thritis or limb amputation; and 4) two patients (one on 
amiodarone, one on placebo) with a single missing data point 
because of ill health and refusal to be tested at that time. 
End-systolic and end-diastolic pixel size was available 
from the nuclear angiographic studies. End-diastolic pixel 
sizes before and after treatment showed that approximately 
a third of the patients in each group had progressive cardiac 
enlargement, whereas the majority showed a reduction in 
cardiac size. However, regardless of whether heart size 
increased or decreased, more patients on amiodarone had a 
clinically significant increase in ejection fraction. A reduc- 
tion in end-systolic pixel size was seen in most amiodarone 
(75%)- and placebo-treated (69%) patients, but the reduction 
was simply “passive” as a result of a smaller end-diastolic 
size with little change in ejection fraction in two-thirds of the 
placebo-treated patients. The reduction in end-systolic pixel 
size was passive in only 25% of the amiodarone-treated 
patients, and the majority of these (including those with 
increased diastolic size) showed an increased ejection frac- 
tion. Overall, the average 16% reduction in end-systolic size 
was greater than that in the placebo-treated patients (9%). 
Exercise tolerance. Exercise tolerance was broadly as- 
sessed as impaired (unable to complete the 21 min protocol) 
or unimpaired (protocol completed). The median duration of 
exercise increased in both groups of patients. In the amio- 
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darone group, it increased from 433 s at baseline to 878 s at 
6 weeks (p < 0.01) and to 907 s at 6 months (p = not 
significant from 6 weeks, but p < 0.05 from baseline). In the 
placebo group, it increased from 757 s at baseline to 900 s at 
6 weeks (p = 0.06) and to 918 s at 6 months. However, 
although the percent of patients with impaired exercise 
tolerance decreased from 88 to 64% in the amiodarone- 
treated patients, it actually increased from 73 to 90% at 6 
months in the placebo-treated patients. Also, aligned rank 
scores in the placebo-treated patients decreased between 6 
weeks and 6 months (p = 0.01) despite little change in 
median exercise duration, such that overall exercise toler- 
ance at 6 months was not significantly different from baseline 
(p = 1 .O). If the patients with impaired exercise tolerance are 
further divided into those only able to exercise for up to 600 s 
(severely impaired) and those able to exercise longer (600 to 
1,260 s), clearer trends in favor of amiodarone are seen 
(Fig. 2). 
Figure 2. Changes in exercise tolerance on a treadmill (Naughton 
protocol) are shown for amiodarone-treated patients (left panel) and 
placebo-treated patients (right panel) before (PRE) and after 6 weeks 
and 6 months of treatment. Patients were further divided into those 
with severe exercise impairment (<600 s exercise duration, solid 
columns) moderate impairment (600 to 1,260 s. hatched columns) and 
no impairment (>1,260 s, open columns). Improvements in exercise 
tolerance (less impairment) in favor of amiodarone are evident. 
Side Efiects and Monitoring Oj’Respiratory, 
Thyroid and Hepatic Function 
Side effects. The following side effects occurred in the 16 
amiodarone-treated patients. 
1) Nausea and anorexia. This was observed only with a 
high dose of the drug (up to 2 weeks) in four patients, with 
two early withdrawals. It was persistent in four patients, and 
two of these patients were withdrawn from the drug after 6 
months of treatment. 
Ventricular arrhythmias. Twelve of the 16 (75%) amio- 
darone-treated patients had frequent premature ventricular 
complexes (21%) at baseline study, and this was reduced to 
25% (4 of 16) at 6 weeks and to 29% (4 of 14) at 6 months. In 
comparison, 64% (9 of 14) of placebo-treated patients had 
frequent premature ventricular complexes at baseline study, 
decreasing to 43% (6 of 14) at 6 weeks and to 33% (4 of 12) 
at 6 months. 
2) Worsening of pre-existing peripheral twuropathy oc- 
curred in one patient who was withdrawn after 6 weeks of 
treatment. 
3) Blue spots in vision were reported in one patient. 
4) Photosensitivify was observed in two patients. 
Thus, both amiodarone and placebo groups showed a 
decrease in the percent of patients with frequent premature 
ventricular complexes over the 6 month observation period 
to 33% and 50% of the baseline value, respectively. How- 
ever, neither decrease reached statistical significance. Ven- 
tricular tachycardia, defined as three or more complexes at 
~120 beatslmin, was seen in 88% (14 of 16) of amiodarone- 
treated patients at baseline study (Fig. 3); by 6 weeks, this 
was reduced to 19% (3 of 16) and at 6 months to 21% (3 of 
14). Only 43% (6 of 14) placebo-treated patients had ventric- 
ular tachycardia at baseline study, increasing to 50% (7 of 14) 
at 6 weeks and to 50% (6 of 12) at 6 months. The relative 
decrease in the percent of patients with ventricular tachy- 
cardia in the amiodarone group reached borderline signifi- 
cance (p = 0.06). 
Figure 3. Changes in the percent of patients with ventricular tachy- 
cardia (three or more complexes at ~120 beatsimin) are shown 
before (PRE) and after 6 weeks and 6 months of treatment. The 
decrease in the percent of patients with ventricular tachycardia in 
the amiodarone group is of borderline significance (p = 0.06). 
VENTRICULAR ARRHYTHMIAS - VT 
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Excluding 1 of the original 19 patients randomized to 
treatment with amiodarone who was an early withdrawal for 
a nondrug-related reason, and accounting for the fact that 
more than one side effect occurred in certain patients, 9 
(50%) of 18 patients had side effects, leading to drug with- 
drawal in 5 (28%). The principal cause for withdrawal was 
nausea, yet 4 (29%) of 14 placebo-treated patients reported 
nausea on occasion during their assessment, although none 
had symptoms severe enough for them to be withdrawn from 
treatment. 
Respiratory function. Before treatment, 10 of the 16 
amiodarone-treated patients had obstructive airway disease 
(forced expiratory volume in 1 s, vital capacity ratio <75%), 
being severe (ratio ~60%) in 2. None had an abnormal 
carbon monoxide diffusing capacity (~60% predicted). Sim- 
ilarly, 11 of the 14 placebo-treated patients had obstructive 
airway disease, severe in 2 and with a low diffusing capacity 
measurement at baseline study in 1. 
The mean carbon monoxide diffusing capacity in the 
amiodarone group at baseline study was 4.3 ? 1.2 ml of 
carbon monoxide/min per mm Hg per liter. Increases and 
decreases in this measurement were seen in individual 
patients during amiodarone treatment over 6 months, but 
decreases dominated to significantly reduce the mean dif- 
fusing capacity by 0.3 at 6 weeks, by 0.4 at 3 months and by 
0.4 at 6 months (all p < 0.01 compared with baseline). The 
placebo group had a mean diffusing capacity of 3.9 of: 1. I at 
baseline study, which was not significantly different from 
that in the amiodarone group. Increases and decreases in this 
measurement also occurred in the placebo group, but were 
evenly balanced so that the mean value decreased by only 
0.01 at 6 weeks and 3 months and by 0.07 at 6 months. The 
mean diffusing capacity for the placebo group at 6 months 
was significantly higher than the mean value for the amio- 
darone group (p < 0.05). 
A decrease in the carbon monoxide diffusing capacity 
of >15% is a sensitive and specific sign of amiodarone 
pulmonary toxicity (14) in a general group of patients. 
However, the majority of amiodarone-treated patients and 
placebo-treated patients showed a decrease in diffusing 
capacity at some time during the 6 month assessment period; 
reductions in 10 placebo-treated patients were as great as 
19% in some patients. Only 3 of 14 amiodarone-treated 
patients had >20% reduction in diffusing capacity and none 
developed clinical evidence of pulmonary toxicity. Thus, the 
majority of reductions in carbon monoxide diffusing capacity 
in amiodarone-treated patients were within the range of 
reductions seen in placebo-treated patients, which were 
presumably due to fluctuations in heart failure status. Thus, 
a decrease in this measurement was not diagnostic of an 
amiodarone effect in this group of patients with heart failure 
unless it exceeded 20%. 
Thyroid function. At baseline study, 15 of the 16 amio- 
darone-treated patients had normal thyroid function, and the 
other was on thyroid replacement therapy with an elevated 
thyroid-stimulating hormone. By 6 months, 8 of the 14 
patients with normal thyroid function had shown a modest 
increase in serum thyroxine, but no depression of thyroid- 
stimulating hormone occurred. Two other patients showed 
new elevations in thyroid-stimulating hormone. None of the 
changes met the criteria for a significant amiodarone-induced 
altered thyroid state (15). No change in thyroid function 
occurred during the assessment period in any placebo- 
treated patient. 
Hepatic function. Fourteen of the 16 amiodarone-treated 
patients had an abnormality of hepatic function at baseline 
study. After 6 months of treatment, hepatic function re- 
turned to normal in five patients, whereas in one patient with 
normal hepatic function at baseline study, it became abnor- 
mal. At baseline study, 5 of the 14 placebo-treated patients 
had abnormal hepatic function; it became abnormal in 2 
additional patients over 6 months. Changes in hepatic func- 
tion did not affect the clinical status of any patient. 
Code breaking. The randomization code was broken in 
seven instances. In five cases, the discovery of active 
amiodarone treatment led to withdrawal of the patient within 
6 months of treatment. In two other patients with sudden and 
marked changes in hepatic or respiratory function, it was 
learned that they were receiving placebo and medication was 
ceased, but this was well after 6 months of treatment. 
Follow-up. All patients underwent long-term follow-up 
evaluation, including those who were withdrawn from treat- 
ment. Nineteen amiodarone-treated patients were followed 
up for between 3 and 30 months (median 23). There were two 
noncardiac deaths from cancer. There were four deaths from 
heart failure and shock, one associated with an acute myo- 
cardial infarction. One of these patients were resuscitated 
from ventricular fibrillation 1 month before dying from heart 
failure. It should be noted that this patient had been with- 
drawn from amiodarone therapy 18 months previously be- 
cause of peripheral neuropathy, and another patient dying of 
heart failure had been off amiodarone for 3 months. Thus, 
the cardiac mortality rate was 21% (4 of 19), but only 11% in 
patients concurrently on amiodarone therapy. 
Fifteen placebo-treated patients were followed up for 
between 5 and 33 months (median 22), and there were two 
deaths from heart failure and shock, four sudden arrhythmic 
deaths and no noncardiac deaths. Another patient was 
successfully resuscitated from an episode of ventricular 
fibrillation. The overall cardiac mortality rate was 40% (6 of 
15). 
Discussion 
Our study demonstrates the beneficial effects of low dose 
oral amiodarone on left ventricular ejection fraction, exer- 
cise tolerance and ventricular arrhythmias in patients with a 
low ejection and history of severe heart failure. 
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Previous studies on amiodarone in congestive heart failure. 
Several studies have examined the effect of long-term oral 
amiodarone therapy on patients with a wide range of ejection 
fractions. Generally, little change in ejection fraction has 
been reported (8.1620), although precipitation of heart 
failure has been attributed to amiodarone with higher doses, 
suggesting some negative inotropic properties (21). How- 
ever, data specifically relating to patients with heart failure 
with a uniformly low ejection fraction treated for a prolonged 
period of time with a low dose of amiodarone (200 mglday) 
are limited, and the effects of amiodarone in these patients 
may be unique and differ from those in other studies using 
different groups of patients and higher drug doses. Our study 
specifically investigated patients with a very low ejection 
fraction before entering the trial, and its placebo-controlled 
design enabled us to allow for any beneficial effects of 
angiotensin-converting enzyme inhibitor or digoxin treat- 
ment (given to the majority of patients) on ventricular 
function (22) and to show improvement in ejection fraction 
attributable to amiodarone therapy. The placebo-controlled 
design is also important because of reports (23) of spontane- 
ous improvement in ventricular function in some patients 
with cardiomyopathy over time. The only other placebo- 
controlled trial (Y) we are aware of failed to show any 
beneficial effect of amiodarone on ejection fraction, but its 
crossover design fpossibly failing to avoid carry over effects 
of amiodarone on the myocardium), shorter duration of 
therapy (3 months) and smaller number of patients with a 
very low ejection fraction may have prevented detection of 
any benefit. 
Effect of amiodarone on ejection fraction and ventricular 
size. Our data revealed favorable trends, particularly in 
end-systolic heart size, in the majority of both placebo- and 
amiodarone-treated patients. The placebo-treated patients 
tended to show a reduction in end-diastolic and end-systolic 
heart size with little change in ejection fraction, probably as 
a result of the angiotension-converting enzyme inhibitor 
treatment usually employed. In contrast, amiodarone ap- 
peared to have a direct inotopic effect in many patients, 
rather than simply acting as a vasodilator, with an increase in 
ejection fraction regardless of any change in end-diastolic 
heart size. resulting in widespread reductions in end-systolic 
heart size. The class III antiarrhythmic action of the drug in 
markedly prolonging the action potential duration may result 
in increased inotropy of the heart (24). The greater improve- 
ment in exercise tolerance in amiodarone-treated patients 
over that in placebo-treated patients may also relate to the 
combined inotropic and vasodilating properties of amio- 
darone compared with an angiotension-converting enzyme 
inhibitor or diuretic drug alone, or both. 
Amiodarone and ventricular arrhythmias. Amiodarone 
can reduce the frequency and complexity of asymptomatic 
ventricular arrhythmias in patients with severe heart failure 
(Y. I I ). A reduction in premature ventricular complexes and 
ventricular tachycardia has also been reported (22,25,26) 
with the use of angiotensin-converting enzyme inhibitors in 
patients with heart failure, but we believe the published data 
can be interpreted as showing a more convincing effect on 
the frequency of premature ventricular complexes than on 
ventricular tachycardia. This may account for the response 
in our placebo-treated patients, such that amiodarone ther- 
apy did not appear to offer any added advantage with respect 
to frequent premature ventricular complexes, but the effects 
on ventricular tachycardia appeared to be greater than any 
benefit angiotensin-converting enzyme inhibitors may have 
given. No proarrhythmic effects of amiodarone were de- 
tected, in that none of the amiodarone-treated patients 
developed ventricular tachycardia during assessment when 
it was not present at baseline (yet this occurred in four of the 
placebo-treated patients). 
Side effects from amiodarone. Generally, the percent of 
patients with side effects from 200 mgiday of amiodarone is 
low, being 6% in one large study (27). Major side effects 
were not dramatically increased in our patients with heart 
failure, yet 50% had some side effect. A particularly irritating 
problem was nausea, which is a common symptom in 
patients with heart failure. We tried to control nausea by 
dividing the dosage, using metoclopramide routinely with 
each dose, and giving the drug postprandially. Nonetheless, 
better strategies to control the emetic side effects of amio- 
darone in patients with heart failure are needed because 
nausea accounted for eight of nine patients with side effects, 
and was responsible for four of the five withdrawals from 
treatment. In general, our monitoring of amiodarone side 
ettects revealed that the detection of some deleterious effects 
(such as hepatic dysfunction and a decrease in carbon 
monoxide diffusing capacity) could be significantly obscured 
and mimicked by changes due to heart failure itself. For 
example, it would seem that a substantial (>20%) and 
persistent lowering of diffusing capacity would be required in 
amiodarone-treated patients with heart failure to cause alarm 
in the absence of other evidence of pulmonary toxicity. 
Amiodarone and cardiac mortality in heart failure. Al- 
though we have demonstrated favorable effects of amio- 
darone on ventricular tachycardia, left ventricular ejection 
fraction. end-systolic size and exercise tolerance, the effects 
of the drug on mortality in patients with heart failure cannot 
be determined from the small number of patients in our study 
and remains uncertain. Initially, encouraging reports from 
nonrandomised trials suggested that a reduction in total 
mortality (10) and even sudden death (11) may be possible. 
However, more recent prospective randomized trials re- 
ported (12) or in progress have not confirmed this, although 
patient numbers are small. It is possible that despite hemo- 
dynamic benefits and suppression of nonsustained ventricu- 
lar tachycardia, low dose amiodarone may be insufficient to 
prevent major arrhythmic events and its inotropic action 
may parallel other inotropic agents in their lack of effect on 
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mortality in patients with heart failure (28). However, we 
suggest that this study shows that amiodarone can at least 
improve patient well-being through improvement in arrhyth- 
mia control and functional capacity. 
We acknowledge the assistance of SANOFI Pty Ltd., United Kingdom and 
Reckitt & Colman Pharmaceuticals, Australia for the provision of placebo 
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